MUMBAI, India, August 14 /PRNewswire/ -- Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUN PHARMA, BSE: 524715) today announced that on August 13, 2008, the U.S. Federal Trade Commission (FTC) granted early termination of the antitrust waiting period under the Hart-Scott-Rodino Act (HSR) for the previously announced Tender Offer by Alkaloida Chemical Company Exclusive Group Ltd. (Alkaloida), a subsidiary of Sun Pharma, for all outstanding Ordinary Shares of Taro Pharmaceutical Industries Ltd. (Taro). Clearance under HSR meets one of the conditions to the Tender Offer. The Offer is scheduled to expire at 5:00 p.m., New York City time, on Tuesday, September 2, 2008 unless extended.

The Offer was commenced on June 30, 2008 in order to comply with the terms of the Option Agreement between Alkaloida and the controlling shareholders of Taro. The complete terms and conditions are set out in the Offer to Purchase, which is filed with the U.S. Securities and Exchange Commission. Taro shareholders may obtain copies of all of the offering documents, including the Offer to Purchase, free of charge at the SEC's website (http://www.sec.gov) or by directing a request to MacKenzie Partners, Inc., the Information Agent for the offer, at 105 Madison Avenue, New York, New York 10016, +1-212-929-5500 (Call Collect) or Call Toll-Free 800-322-2885, Email: tenderoffer@mackenziepartners.com.

Greenhill & Co., LLC is acting as the Dealer Manager for the Tender Offer and MacKenzie is acting as the Information Agent for the Tender Offer.

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, U.S. and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, and orthopedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at http://www.sunpharma.com.

Contacts Uday Baldota Mira Desai Tel +91-22-6645-5645, Xtn 605 Tel +91-22-6645-5645, Xtn 606 Tel Direct +91-22-66455605 Tel Direct +91-22-66455606 Mobile +91-98670-10529 Mobile +91-98219-23797 E mail uday.baldota@sunpharma.com E mail mira.desai@sunpharma.com Brunswick Group for Sun Pharma MacKenzie Partners Nina Devlin / Erin Becker Robert Marese +1-212-333-3810 +1-212-929-5500 Arad Communications for Sun Pharma Greenhill Gali Dahan Ashish Contractor +972-3-7693320 +1-212-389-1537

Contacts: Uday Baldota, Tel +91-22-6645-5645, Xtn 605, Tel Direct +91-22-66455605, Mobile +91-98670-10529, E mail uday.baldota@sunpharma.com; Mira Desai, Tel +91-22-6645-5645, Xtn 606, Tel Direct +91-22-66455606, Mobile +91-98219-23797, E mail mira.desai@sunpharma.com; Brunswick Group for Sun Pharma, Nina Devlin / Erin Becker, +1-212-333-3810; MacKenzie Partners, Robert Marese, +1-212-929-5500; Arad Communications for Sun Pharma, Gali Dahan, +972-3-7693320; Greenhill, Ashish Contractor, +1-212-389-1537